Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
33 studies found for:    "Chronic inflammatory demyelinating polyneuropathy"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: NPB-01
2 Unknown  Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention:
3 Withdrawn High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: Cyclophosphamide
4 Completed
Has Results
Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Biological: 10% liquid formulation of human immunoglobulin
5 Completed Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
Conditions: CIDP;   Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: lipoic acid
6 Active, not recruiting Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy;   Polyradiculoneuropathy
Interventions: Biological: IgPro20;   Biological: Placebo;   Biological: IgPro10
7 Active, not recruiting Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Biological: hematopoietic stem cell transplantation
8 Active, not recruiting Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP);   Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Intervention: Biological: IgPro20
9 Completed Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Intervention: Drug: Interferon Beta-1a
10 Active, not recruiting Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: Drug: Fingolimod;   Drug: Placebo Comparator
11 Recruiting Subcutaneous Immunoglobulin for CIDP
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: Immune Globulin Subcutaneous (Human)
12 Recruiting IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: Intravenous Immunoglobulin
13 Completed Effect of Resistance and Aerobic Exercise in CIDP or MMN
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy;   Multifocal Motor Neuropathy
Interventions: Other: Resistance training;   Other: Aerobic training
14 Completed Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Conditions: Demyelinating Diseases;   Paraproteinemias
Intervention: Drug: intravenous immunoglobulin (IVIg)
15 Withdrawn Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: H.P. Acthar® Gel
16 Recruiting IVIg for Demyelination in Diabetes Mellitus
Conditions: Peripheral Neuropathy;   Diabetes Mellitus;   Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: Drug: 10% intravenous immunoglobulin (IVIg);   Drug: 0.9% sodium chloride
17 Completed Immunoglobulin Dosage and Administration Form in CIDP and MMN
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy;   Multifocal Motor Neuropathy;   Hemolytic Anemia
Intervention: Drug: Immunoglobulins
18 Not yet recruiting Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: Procedure: Muscle Magnetic Resonance Imaging (RMI) evaluation;   Device: MRI
19 Enrolling by invitation MRI in Diagnosing and Monitoring CIDP
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Intervention:
20 Recruiting Efficacy and Safety Study of I10E in Treatment of Patients With CIDP
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Intervention: Drug: I10E

   Previous Page Studies Shown (1-20) Next Page (21-33) Show next page of results    Last Page
Indicates status has not been verified in more than two years